Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.
about
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus.Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes.Management of Type 1 Diabetes in Older Adults.Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.Long-acting basal insulin analogs: latest developments and clinical usefulness.Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein.
P2860
Q33884391-5FBF4D5D-43A4-4ED8-97BE-DF28F965E9A2Q34468769-99A69267-648F-4D8E-90C5-1894C3C2825FQ35786400-DE01B0A4-BBC5-463F-8026-730ABDE065E4Q35910466-7A2CD68D-9E6F-4B57-8094-F20AD439C57DQ36334638-1FED771E-B326-4EF6-B878-6DF8280B291BQ36515474-5620D08E-CD28-45B1-86F1-56966B148DE1Q38241834-5E5E20E1-94B5-431F-923F-C9C951BB7B0EQ38858785-A3FFBB8F-2A05-4F29-A9CD-4DBCA77A2157Q38970550-43348223-EA82-4600-A9E6-F18CF59AF8B9Q42329441-31D181D2-3988-4DD0-87E0-81EE35A57E9BQ47371507-8332FDFD-0730-4BBD-BAEB-D5A3F5F72AEF
P2860
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glargine and detemir: Safety a ...... -acting basal insulin analogs.
@en
Glargine and detemir: Safety a ...... -acting basal insulin analogs.
@nl
type
label
Glargine and detemir: Safety a ...... -acting basal insulin analogs.
@en
Glargine and detemir: Safety a ...... -acting basal insulin analogs.
@nl
prefLabel
Glargine and detemir: Safety a ...... -acting basal insulin analogs.
@en
Glargine and detemir: Safety a ...... -acting basal insulin analogs.
@nl
P2860
P356
P1476
Glargine and detemir: Safety a ...... -acting basal insulin analogs.
@en
P2093
Allen B King
Kitty Poon
P2860
P304
P356
10.2147/DHPS.S7301
P407
P577
2010-10-28T00:00:00Z